Generalised pustular psoriasis (GPP) prevalence in England climbed by more than 50% between 2008 and 2022, while patients faced substantially higher mortality risks and reduced life expectancy compared to people without the condition.
GPP Prevalence and Incidence Trends in England
Analysing primary care and hospital records linked with mortality, ethnicity, and deprivation data across a cohort of 25.8 million people, researchers identified 991 patients with GPP. The study tracked a distinct upward trajectory in disease frequency over the 15-year observation window. GPP prevalence rose from 20.9 per million individuals in 2008 to 32.5 per million in 2022. Meanwhile, incidence remained stable through 2016 before climbing to reach 4.9 per million person-years.
Demographic breakdowns within the study cohort revealed clear disparities in who develops the condition. Females accounted for 63% of identified GPP patients. The broader population breakdown showed that 86% of patients were White, 10% were Asian, and 3% were Black, Mixed, or Other. The mean age at GPP onset was 51.4 years, though Asian patients experienced disease onset earlier than their White counterparts.
Elevated Mortality Risk and Specific Causes of Death
Patients diagnosed with GPP faced more than three times the risk of all-cause mortality compared to individuals without the condition, yielding an adjusted hazard ratio of 3.19 with a 95% confidence interval between 2.58 and 3.91. Beyond overall death rates, researchers noted elevated risks across several specific disease categories, including neoplasms, as well as respiratory, digestive, and circulatory diseases.
The strongest association uncovered in the mortality analysis involved sepsis. Patients with GPP experienced a dramatically higher sepsis mortality risk, reflected in an adjusted hazard ratio of 9.76 and a 95% confidence interval ranging from 4.92 to 19.35. Because the investigation relied on an observational design, the data identifies strong epidemiological associations rather than proving that GPP directly caused the recorded mortality outcomes.
Life Expectancy and Clinical Burden
Life expectancy was notably reduced among GPP patients, with younger ages at the time of diagnosis correlating directly with the greatest reduction in expected lifespan. The study authors noted that the rising prevalence figures, combined with distinct variations across sex and ethnicity and the starkly elevated mortality risks, demonstrate a substantial clinical burden. They emphasized an urgent need for targeted clinical strategies aimed at reducing preventable morbidity and mortality for high-risk patient groups.
Related reading